Based on drug interaction trial results, omeprazole can be coadministered with dolutegravir without a dose adjustment. Coadministration of omeprazole (40 mg once daily) and dolutegravir (50 mg single dose) to 12 subjects decreased dolutegravir Cmax, AUC and Ctrough by 8%, 3% and 5%, respectively.

 

Coadministration of omeprazole (40 mg once daily) and single doses of dolutegravir (50 mg, administered 2 hours after omeprazole) was studied in 12 HIV-negative subjects. Omeprazole coadministration had no significant effect on dolutegravir exposure (no change in AUC, 8% decrease in Cmax, 5% decrease in Cmin). Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment as solubility of dolutegravir is not influenced by changes in gastric pH and coadministration with omeprazole had minimal effect on dolutegravir exposure.